Literature DB >> 10559532

Vaccine injury compensation programs worldwide.

G Evans1.   

Abstract

Approximately a dozen countries provide some form of compensation for injuries (or deaths) following vaccination. More than anything else, they were instituted in the belief governments have a special responsibility to those injured by properly manufactured and administered vaccines used in public health programs. Administratively, most are managed through the national government, including decisions on eligibility for and amount of compensation. Eligibility may depend on the recipient's age, citizenship or residency status, category of vaccine (e.g., recommended, compulsory), the location it is administered (public vs private ambulatory setting), or satisfying certain time frames for filing a claim. Since few vaccine-related injuries have a clinical or laboratory marker, proving actual causation is difficult. Causation decisions are usually based on the balance of probabilities standard of more likely than not. All countries require that the effects be long lasting (e.g., greater than 6 months), and nearly all provide coverage for medical costs, disability pensions, and death benefits, while noneconomic damages (pain and suffering) are included much less frequently. Funding is generally from the national treasury, with some programs receiving support from lower governmental entities or vaccine manufacturers. After nearly 4 decades of operation, vaccine injury compensation program appears to be an increasingly accepted component of immunization programs today. While we have a much better understanding of their statutory purpose, frame work, process and outcome, there is much more to be learned. Future research should focus on vaccine compensation programs and (1) decision-making at the administrative level; (2) the utilization of outcome indicators in order to gauge effectiveness, including immunization acceptance; (3) the knowledge and attitudes of the public and medical community in host countries; and (4) the overall perspective of vaccine manufacturers. Insight into these and other areas will no doubt aid other countries as they consider implementing programs of their own.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10559532     DOI: 10.1016/s0264-410x(99)00291-1

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  The case for a vaccine injury compensation program for Canada.

Authors:  Kumanan Wilson; Jennifer Keelan
Journal:  Can J Public Health       Date:  2012 Mar-Apr

2.  Protecting vaccine programs and the public.

Authors:  Kumanan Wilson
Journal:  CMAJ       Date:  2007-06-05       Impact factor: 8.262

Review 3.  Performance of the United States Vaccine Injury Compensation Program (VICP): 1988-2019.

Authors:  Kimberly M Thompson; Walter A Orenstein; Alan R Hinman
Journal:  Vaccine       Date:  2020-01-22       Impact factor: 3.641

Review 4.  No-fault compensation following adverse events attributed to vaccination: a review of international programmes.

Authors:  Clare Looker; Heath Kelly
Journal:  Bull World Health Organ       Date:  2011-03-21       Impact factor: 9.408

5.  Physicians' recommendations to their patients concerning a novel pandemic vaccine: a cross-sectional survey of the 2009 influenza A/H1N1 pandemic in Japan.

Authors:  Yusuke Inoue; Kenji Matsui
Journal:  Environ Health Prev Med       Date:  2010-12-25       Impact factor: 3.674

6.  The Ebola Vaccine, Iatrogenic Injuries, and Legal Liability.

Authors:  Amir Attaran; Kumanan Wilson
Journal:  PLoS Med       Date:  2015-12-01       Impact factor: 11.069

7.  Global landscape analysis of no-fault compensation programmes for vaccine injuries: A review and survey of implementing countries.

Authors:  Randy G Mungwira; Christine Guillard; Adiela Saldaña; Nobuhiko Okabe; Helen Petousis-Harris; Edinam Agbenu; Lance Rodewald; Patrick L F Zuber
Journal:  PLoS One       Date:  2020-05-21       Impact factor: 3.240

8.  Vaccine adverse events reported during the first ten years (1998-2008) after introduction in the state of Rondonia, Brazil.

Authors:  Mônica P L Cunha; José G Dórea; Rejane C Marques; Renata S Leão
Journal:  Biomed Res Int       Date:  2013-02-14       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.